C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression
TL;DR: These studies illustrate the integration and collaboration of Wnt pathways in basal-like breast cancer, where Ror2 provides a spatiotemporal function to regulate the balance of WNT signaling and cellular heterogeneity during tumor progression.
Journal ArticleDOI
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer
Christian D. Young,Lisa J. Zimmerman,Daisuke Hoshino,Luigi Formisano,Ariella B. Hanker,Michael L. Gatza,Meghan M. Morrison,Preston D. Moore,Corbin A. Whitwell,Bhuvanesh Dave,Thomas Stricker,Neil E. Bhola,Grace O. Silva,Premal Patel,Dana M. Brantley-Sieders,Maren K. Levin,Marina Horiates,Norma Alonzo Palma,Kai Wang,Philip J. Stephens,Charles M. Perou,Alissa M. Weaver,Joyce O'Shaughnessy,Joyce O'Shaughnessy,Jenny C. Chang,Ben Ho Park,Daniel C. Liebler,Rebecca S. Cook,Carlos L. Arteaga +28 more
TL;DR: Treatment with EGFR inhibitors reduced growth of PIK3CA mutant BLBC cell lines and murine mammary tumors driven by a PIK 3CA mutant transgene, all together suggesting that Pik3CA mutations promote tumor growth in part by inducing protein changes that activate EGFR.
Proceedings ArticleDOI
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes
Aleix Prat,Olga Karginova,Joel S. Parker,Cheng Fan,Xiaping He,Lisa M. Bixby,J. Chuck Harrell,Erick Roman,Barbara Adamo,Melissa A. Troester,Charles M. Perou +10 more
TL;DR: The results presented here help to improve the understanding of the wide range of breast cancer cell line models through the appropriate pairing of cell lines with relevant in vivo tumor and normal cell counterparts.
Journal ArticleDOI
Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation
Ze-Yi Zheng,Lin Tian,Wen Bu,Cheng Fan,Xia Gao,Hai Wang,Yi-Hua Liao,Yi Li,Michael T. Lewis,Dean P. Edwards,Thomas P. Zwaka,Susan G. Hilsenbeck,Daniel Medina,Charles M. Perou,Chad J. Creighton,Xiang Zhang,Eric C. Chang +16 more
TL;DR: BLBC progression is promoted by increasing activities of wild-type N-Ras, which mediates autocrine/paracrine signaling that can influence both cancer and stroma cells.
Journal ArticleDOI
CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).
William M. Sikov,Mei Yin C. Polley,Erin Twohy,Charles M. Perou,Baljit Singh,Donald A. Berry,Sara M. Tolaney,George Somlo,Elisa R. Port,Cynthia X. Ma,Charles S. Kuzma,Eleftherios P. Mamounas,Mehra Golshan,Jennifer R. Bellon,Deborah Collyar,Olwen Hahn,Clifford A. Hudis,Eric P. Winer,Ann H. Partridge,Lisa A. Carey +19 more
TL;DR: CALGB 40603 is a 2x2 randomized trial that previously demonstrated that adding Cb to NACT signified activity when combined with standard chemotherapy in TNBC.